Metrocreme (Metronidazole)

Metronidazole penetrates bacterial cells and is reduced to reactive intermediates that damage DNA, inhibiting nucleic acid synthesis in anaerobic microorganisms. In the skin, it also dampens inflammatory pathways, reducing cytokine release and leukocyte activity, which helps control inflammation.

The dosage of Metrocreme is determined by the prescribing clinician based on the specific indication, severity of the condition, and patient factors. The prescriber will provide instructions on the amount to apply and frequency of use.

Safety data for topical metronidazole in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Metrocreme to pregnant or breastfeeding individuals.

To order Metrocreme, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metrocreme’s metronidazole offers both antimicrobial and anti‑inflammatory actions, which distinguishes it from many topical antibiotics that primarily target bacteria. Compared with agents such as clindamycin, metronidazole may be preferred for patients with inflammatory lesions and a risk of anaerobic infection.

Metrocreme should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain its stability and efficacy.

Metrocreme is applied topically to clean, dry skin. A thin layer is spread over the affected area, usually once or twice daily, as directed by the prescriber. Hands should be washed before and after application.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and rare systemic neurotoxicity if significant absorption occurs. Patients should seek immediate medical attention if they notice signs of severe skin reactions or systemic symptoms.

Metrocreme should be avoided in individuals with known hypersensitivity to metronidazole or any component of the formulation, and in patients with extensive open wounds or severe skin barrier disruption unless specifically advised by a healthcare professional.